Aurelie Mahalatchimy
Overview
Explore the profile of Aurelie Mahalatchimy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
35
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mahalatchimy A, Lau P, Li P, Flear M
J Law Biosci
. 2021 Aug;
8(2):lsaa080.
PMID: 34408900
Gene-editing technologies, ie those able to make changes in the DNA of an organism, are the object of global competition and a regulatory race between countries and regions. There is...
2.
Mahalatchimy A, De Grove-Valdeyron N
J Int Bioethique Ethique Sci
. 2019 Feb;
29(2):35-51.
PMID: 30767446
In relation to the ?hot? topic of regenerative medicine, European Union law established a specific legal framework for advanced therapy medicinal products, manufactured from human or animal genes, cells or...
3.
Rial-Sebbag E, Mahalatchimy A, Duguet A
J Int Bioethique Ethique Sci
. 2018 Mar;
28(2):107-129.
PMID: 29561103
To encourage and maximise the use of human biological material in Europe, the European Commission instigated a main Directive in 2004 (Directive 2004/23/EC), four technical ones in 2006 (Commission Directives...
4.
Mahalatchimy A, Faulkner A
Regen Med
. 2017 Oct;
12(6):611-622.
PMID: 28972450
Aim: This paper aims to map the trends and analyze key institutional dynamics that constitute the policies for reimbursement of regenerative medicine (RM), especially in the UK. Materials & Methods:...
5.
Mahalatchimy A
Med Law Rev
. 2016 Apr;
24(2):234-58.
PMID: 27083495
Cell-based regenerative therapies are presented as being able to cure the diseases of the twenty-first century, especially those coming from the degeneration of the aging human body. But their specific...
6.
Gardner J, Faulkner A, Mahalatchimy A, Webster A
Regen Med
. 2015 Nov;
10(7):885-95.
PMID: 26541074
There is concern that translation 'from bench to bedside' within regenerative medicine (RM) will fail to materialize, or will be dismally slow, due to various challenges arising from the highly...
7.
Mahalatchimy A, Rial-Sebbag E, Duguet A, Taboulet F, Cambon-Thomsen A
Nat Biotechnol
. 2015 Jan;
33(1):41-3.
PMID: 25574634
No abstract available.
8.
Chabannon C, Sabatier F, Rial-Sebbag E, Calmels B, Veran J, Magalon G, et al.
Med Sci (Paris)
. 2014 Jun;
30(5):576-83.
PMID: 24939546
Regulation (EC) n° 1394/2007 from the European Parliament and the Council describes a new category of health products termed « Advanced Therapy Medicinal Products » (ATMPs). ATMPs derive from cell...
9.
Anastasova V, Mahalatchimy A, Rial-Sebbag E, Anto Boque J, Keil T, Sunyer J, et al.
Pediatr Allergy Immunol
. 2013 May;
24(4):389-94.
PMID: 23692330
Background: Communicating results to research participants is an issue frequently discussed in terms of ethics. It has specific features when involving large-scale paediatric cohorts. High-throughput biological explorations reveal also incidental...
10.
Mahalatchimy A, Rial-Sebbag E, De Grove-Valdeyron N, Tournay V, Cambon-Thomsen A, Duguet A, et al.
Med Law
. 2012 Aug;
31(1):25-42.
PMID: 22908736
The European Medicines Agency (EMA) is a European Agency as it is a decentralized body governed by European public law; it has its own legal personality and is also distinct...